A fungus-growing ant, Atta colombica, tends its garden. These ants carry symbiotic Pseudonocardia bacteria that produce compounds to control the growth of parasitic fungi on the "crop" fungi the ants use for food. (Photo courtesy of Cameron Currie, University of WisconsinMadison.) 
Attine ants that cultivate fungi carry antibiotic-producing bacteria that suppress parasitic microfungi in those fungal gardens. Specialized structures for maintaining these bacteria apparently developed very early in the history of fungus gardening, at least 50 million years ago, according to Cameron R. Currie of the University of Wisconsin, Madison, and his collaborators, who report these findings in the January 6, 2006, issue of Science.
"You can't argue that the bacterial players are secondary," Currie says, stressing the importance of this point. "The structures on ants can completely cover the exoskeleton. It appears that the ants are more morphologically modified for growing the bacteria than they are for growing their fungus gardens." Specifically, these farmer ants have specialized crypts that contain exocrine glands, in which they maintain bacteria. The integumental structures are absent among ants that do not grow fungi, and have changed extensively since the fungus-cultivating ants emerged.
"Their findings reveal that these evolutionary changes happened in the ancestor of the fungus-cultivating attine ants, which invariably associate with mutualistic Pseudonocardia bacteria," says Jacob A. Russell of Harvard University in Cambridge, Mass., who was not involved in the research. The long-lived symbiosis suggests that the bacteria suppressed any resistance that might have developed in the parasitic microfungi, all members of the genus Escovopsis. Besides their role in fungus gardening, little is known about Pseudonocardia, except that they are also found in soil and compost.
This long-term suppression of resistance leads other researchers to wonder whether understanding this system might provide insights about suppressing the development of resistance to other types of antibacterial or antifungal agents such as those that are used in combating human pathogens. "The complex symbiotic relationship among attine ants, their fungal cultivars, which they cultivate for food, specialized garden parasites, which sometimes overgrow the fungus garden, and parasite-inhibiting bacteria, which produce antibiotics to control parasites is . . . amazing," says microbiologist Philip Tierno, Jr. of the New York University Medical Center in New York, N.Y.
Tierno is especially impressed that parasite-inhibiting bacteria proved "effective at inhibiting their corresponding garden parasites for millions of years without the development of resistance to the antibiotic products that they produce." Learning more about the mechanisms underlying this phenomenon eventually might lead us to apply these "mechanisms to our own antibiotic therapy of infectious disease to either reduce or prevent development antibiotic resistance for the benefit of humankind."
Multiple antibiotics might be acting in concert, preventing development of resistance to any single compound or preventing parasitic fungi from be-coming resistant, says Stuart Levy of Tufts University School of Medicine in Boston, Mass. However, he adds, it is unlikely that the ant-associated, symbiotic Pseudonocardia bacteria developed a simple or single, resistanceproof antifungal compound. He also points out that pathogens that infect humans still show no generalized resistance to human antibacterial defenses-small peptides, called defensins and magainins-although bacteria can develop resistance in vitro when exposed to a single one of these compounds.
Another complicating factor is that the ants behavior bolsters the biochemical effects of the antifungal molecules that their symbiotic Pseudonocardia bacteria produce. "We infected nests with the parasite, and videotaped the ants," Currie says. The ants first "cleaned the mycelia by running their mouthparts over the fungus. If the infection became established, they would resort to weeding the fungus garden."
Thomas Belt began studying fungus-gardening ants in the 19th century. In 1874, he reported that the ants use leaves as "manure to grow fungal gardens on which to feed." More than a century later in the late 1990s, Currie and his collaborators identified the crucial role played by symbiotic bacteria and the antibiotics that they produce in maintaining this miniature agricultural system. Specifically, they revealed that white spots on the ants, previously described merely as "waxy blooms," are specially maintained bacterial colonies. The easy-to-apply dressing may one day become a means for treating burn victims on battlefields, she says. The polyurethane-hydrogel material, which looks like solid foam with a shiny, transparent overlay, is made in collaboration with Avitar Inc. of Canton, Mass. The experimental dressing and two commercially available polyurethane dressings were immersed in solutions containing antimicrobials such as chlorhexidine or chloramphenicol, or in phosphate-buffered saline before being tested for their ability to prevent wound infections.
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The relative potencies of the dressings were assessed in vivo by applying each of the dressings to surgically inflicted wounds on the backs of Yorkshire pigs, and then testing periodically during several days for outgrowth of pathogens and other indications of infections. The wounds of some of those animals were inoculated with 10 7 cells of Pseudomonas aeruginosa, Staphylococcus aureus, or Fusobacterium sp. shortly before the dressings were applied.
Infections were rampant among those animals treated with salinetreated polyurethane or polyurethanehydrogel dressings. However, for those animals whose wounds were covered by hydrogels that were loaded with chlorhexidine or chloramphenicol, bacterial numbers remained below a threshold of 10 5 /g for up to 4 days, enabling the wounds to heal. The polyurethane dressings were not so effective as the polyurethane-hydrogel combination dressings, and none of the dressings did well in controlling Fusobacterium sp., according to Martineau and her collaborator Pang Shek.
Not only do hydrogel dressings effectively protect against some bacterial infections, they also absorb more wound exudate than do their polyurethane counterparts. Also, the hydrogel's local skin-cooling effects help to reduce dressing-related collateral damage, according to Martineau.
The DRDC researchers hope that their research will lead to products for burn victims, including those who are wounded in battle. Canadian surgeons and medics in the Middle East report an increase in burn injuries over past military campaigns, apparently a consequence of the increased use of blast weapons. Such burn injuries are especially vulnerable to infection, but in battle, immediate care "often involves your buddy beside you," Martineau points out. Someday, packages containing drug-loaded hydrogel patches may be standard combat issue. However, such hydrogel dressings also could be used for the treating burns that occur in other settings, including at home. "Our proofof-principle study indicates the commercial potential," she says. This conclusion comes following a DNA-based analysis of transcripts produced by 12 multidrug-resistant MRSA clinical isolates and two prototypical laboratory strains-one MRSA and the other methicillin-susceptible (MSSA). The comparisons also included a battery of established genomic and minimal inhibitory concentration tests.
Brian Hoyle
Surprisingly, the agr quorum-sensing system that regulates a battery of virulence factors in S. aureus does not appear to be induced among clinical MRSA isolates. However, genes encoding efflux pumps, which expel antibiotics, are generally up-regulated among those isolates. Moreover, among those strains that are resistant to many kinds of antibiotics, expression of peptidoglycan-associated genes, including penicillin-binding proteins, is enhanced. Whether changes in the peptidoglycan genes lead to thickening of the cell walls is an open question, says Malouin.
"Prototypical S. aureus strains secrete exotoxins and hydrolytic enzymes while repressing colonization factors during the transition from the early to the late-exponential phase in vitro, and it is generally accepted that such a modulation accounts for the progression of the disease in vivo and the ability of S. aureus to cause a wide variety of infections," Malouin says. One consequence of the nonactivation or delayed activation of agr is that isolates from persistent infections "express specific sets of genes differently than that generally observed in prototypical strains." A silenced agr system amid genes encoding cell surface components being enhanced could mean that S. aureus follows "a stealth strategy" to persist instead of being aggressively virulent, Pruneau and Malouin suggest. "The major challenge for S. aureus in the hospital environment and [intensive care unit] is to survive under constant antibiotic pressure and less so to survive in hosts with a healthy immune system," Malouin notes. "It is generally accepted that there is a physiological cost for resistance, and we believe that multiresistant S. aureus may differ from prototypical laboratory strains in terms of fitness, virulence, or strategies to colonize or invade hosts . . . MRSA strains found in the community generally present higher growth rates than multiresistant MRSA strains but are resistant to fewer classes of antibiotics and show lower levels of resistance."
Malouin plans to test whether innate and adaptive host responses toward multiresistant S. aureus differ from responses to prototype strains. "No one has systematically compared host responses to groups of diseasespecific strains or multiresistant isolates," he says.

Race to New Antibiotics Is Slow, Fragmented
The race for new antibiotics is a fragmented event, and researchers who persist in it tend to find themselves headed in disparate directions and moving at a less-than-blistering pace. Amid the frustrations, however, are discrete signs of forward progress toward promising new drug entities, according to several researchers who presented their respective findings during the "Poster Summary Session" at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last December in Washington, D.C.
More on Influenza and Planning for a Pandemic
Here are several noteworthy developments regarding the annual influenza epidemic and plans for dealing with a potential flu pandemic:
• Health and Human Services (HHS) Secretary Mike Leavitt in January announced $100 million in funding to support state and local preparedness for pandemic influenza, with a focus on practical, community-based procedures that could prevent or delay the spread of influenza, and reduce the burden of illnesses. By early 2006, 39 states had shared their pandemic flu plans with HHS.
• At the end of 2005, President Bush signed a Defense Appropriations Bill with provisions blocking liability suits against producers of vaccines that protect against epidemics unless their producers can be proved guilty of willful misconduct.
• Officials at the Centers for Disease Control and Prevention (CDC) in mid-January advised clinicians not to prescribe two common antivirals, amantadine and rimantadine, for influenza during the current season because lab testing indicates that the predominant circulating H3N2 strain is resistant to these drugs.
• GlaxoSmithKline in London, United Kingdom, applied to the European Medicines Agency early in January for preliminary approval of its "core" vaccine against pandemic influenza-part of a process enabling companies to conduct clinical trials for safety and to establish dosage and schedule for such products.
Some drug development projects are narrowly focused from the outset, with the impetus being a search for a drug for treating a single type of pathogen. For example, Boudeqijn de Jonge and his collaborators at AstraZeneca R&D in Waltham, Mass., are studying a series of pyrazolopyrimidinediones that interfere specifically with Helicobacter pylori, a bacterial pathogen that can give rise to ulcers in the upper gastrointestinal (GI) tract. Although effective multidrug regimens are available for treating such infections, patient compliance is "poor" and drug resistance can also be a problem, he says. The AstraZeneca group is seeking a drug that, ideally, could be used alone, taken once daily, and would minimally disturb microbial flora of the lower GI.
The new pyrazolopyrimidinediones, which are "amenable to mutiparallel syntheses," act on a glutamate racemase that yields the D form of this amino acid for synthesizing the cell wall of these bacteria, according to de Jonge. Although bioavailability and serum half-lives are less than ideal, the minimal inhibitory concentrations (MICs) for some of the compounds in this series are in the 1 g/ml range, he notes. Chemists in the group find these compounds relatively easy to modify, and they continue to develop candidates in an effort to optimize in vivo activities within this set of potent H. pylori-directed inhibitors.
The search for new compounds that target Mycobacterium tuberculosis also provides a narrowly focused drug-pursuit philosophy. In this case, the investigators aimed to exploit the peculiarly lipid-rich qualities of this microorganism, leading them to the promising candidate compound, designated OPC-67683, which is a novel imicazo-oxazole, according to Makoto Matsumoto of Otsuka Pharmaceutical Co. in Tokushima, Japan, and his collaborators there and at a medical center in Osaka. This compound proved the "most potent in vitro among all tested drugs, including the standard drugs used for treating TB patients," he says.
OPC-67683 acts against M. tuberculosis by inhibiting mycolic acid synthesis, thus disrupting the cell walls and killing these bacteria, according to Matsumoto. The compound retains activity when tested against multidrug-resistant clinical isolates, and it also is highly active when tested in mice that are infected with this pathogen. Further, it also works effectively and appears to be safe when tested in immunocompromised mice, suggesting that this promising compound could find use among TB patients whose immune systems are impaired because they also are infected with HIV.
Another search, but for broaderspectrum antibiotics, is based on expanding the carbacephem family of drugs-in particular, by producing a series of heteroarylthio derivatives, according to George Miller of Blanca Pharmaceuticals in Mountain View, Calif., and his collaborators there and at NAEJA Pharmaceuticals in Edmonton, Alberta, Canada, and the Polish Academy of Science in Warsaw, Poland. This series of new drug candidates is aimed primarily at countering the expanding prevalence of methicillin-resistant Staphylococcus aureus (MRSA) and similar gram-positive pathogens such as penicillin-resistant Streptococcus pneumoniae. However, a few oddball gram-negative species are also in the mix, including Moraxella catarrhalis, a sometime pathogen of the upper respiratory tract and middle ear.
Among this set of carbacephem derivatives, a compound designated BP-102 is considered the "most advanced," Miller says. This non-zwitterionic compound is active against all those pathogens in vitro, as well as simple ␤-lactamase-producing isolates of Escherichia coli, and it also shows good safety and pharmacokinetic properties, including low binding to serum proteins and about a two-hour halflife when tested in rodents. Further, he adds, the compound is highly soluble, has high pathogen-killing activity in vivo, and appears suitable for intravenous formulation.
Rifamycin is another established
Viral Envelope Protein Change Key to Cell Entry
The F protein of parainfluenza virus, a member of the paramyxovirus family, resides in the viral envelope in a metastable state, ready to fuse with the outer membranes of target cells that this virus infects. Once contact is made, the F protein dramatically changes shape, releasing viral RNA into the target cell as the two membranes blend, according to Theodore Jardetzky, Robert Lamb, and their collaborators at Northwestern University in Evanston, Ill., who reported their findings last January in Nature DOI: 10.1038/nature04322. To analyze this shape change, the researchers replaced part of the membrane segment of the viral F protein in a way that allowed the metastable, prefusion conformation of this modified protein to be crystallized and then subjected to high-intensity X-rays. Their subsequent structural comparisons of the two forms of this protein reveal "dramatic rearrangements" and suggest that it "breaks a lot of rules about protein folding," Jardetzky says. These insights could prove general for other membrane proteins of viruses in this family, including those responsible for mumps and measles, as well as human respiratory syncytial virus, canine distemper virus, and rinderpest virus. 
Global Warming Tied to Fungal Outbreaks in Frogs
The chytrid fungus Batrachochytrium dendrobatidis is devastating harlequin frogs and other amphibian species throughout Central and South America, and these regional outbreaks and die-offs are striking evidence of global warming, according to J. Alan Pounds at the Monteverde Cloud Forest Preserve in Costa Rica and his collaborators, whose report appears in the January 12, 2006, Nature. Based on their analysis of records of sea-surface and air temperatures, Pounds and colleagues say that harlequin frogs are disappearing in parallel with changing climate. Thus, rising temperatures enhance cloud cover on tropical mountains, leading to cooler days and warmer nights, both of which favor the chytrid fungus, which grows optimally between 17 and 25°C. The message of this study "goes beyond amphibians," says Sam Scheiner, program director in the National Science Foundation division of environmental biology, which is supporting this research. He calls global warming and the accompanying emergence of infectious diseases "a real and immediate threat to biodiversity." three equal doses of the vaccine, and each dose carries a total of 8 ϫ 10 7 plaque-forming units (PFU), which is a much higher dose than came when RotaShield was being administered, he says. The bovine virus used in the newer vaccine is "much less welladapted to grow in the human intestine . . . and there is less shedding of this virus," he points out. The strategy in designing and using RotaTeq aims at "front-loading the antigen because this virus replicates less well than does the primate-based virus in RotaShield." Despite some sacrifice in immunogenicity, there is a gain in safety, and adverse events are "rare."
The other of these two newer vaccines, GSK's Rotarix, is based on a live-attenuated, monovalent, humantype rotavirus, according to RuizPalacios. It is administered to young children in two oral doses, and proved both safe and efficacious during a large-scale international clinical trial involving more than 63,000 children in Finland and 11 countries in Latin America, he says.
The Mexican cohort of that clinical trial included 5,298 children, half of whom received vaccine and the other half a placebo, according to RuizPalacios. There were 12 cases of severe gastrointestinal illnesses among the placebo group, but only one among those who received the vaccine. The vaccinated group experienced a 92% reduction in severe bouts of rotavirus-attributable gastritis, and a 69% reduction in cases of gastritis of any etiology, he says. All in all, two doses of vaccine had "a significant impact, [reducing] the burden of disease for the Mexican cohort."
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HIV Vaccine Design Is Based on Computed Consensus Sequences
Scientists are developing a new vaccine design strategy to overcome the challenges of HIV diversity. Their strategy entails identifying and making artificial antigens, based on analyzing sequence information contained in a large HIV-1 subtype databank, according to team members Bette Korber, an immunologist with the Theoretical Biology and Biophysics Group at Los Alamos National Laboratory (LANL) in Los Alamos, N.M, and Tammoy Bhattacharya, a LANL high-energy physicist.
"The failure to produce effective and broad-based protection against HIV shows we need to rethink vaccine discovery strategies," Korber says. HIV diversity, resulting from frequent mutations and gene exchanges among replicating viruses, makes vaccine design difficult.
Indeed, the task is far more challenging than it is to annually redesign influenza vaccines to accommodate a 2% amino acid change, according to Korber. In contrasting the relative diversity of the two viruses, she says, "The same year when researchers found 96 influenza strains throughout the world, other researchers discovered 193 HIV strain variations in the Democratic Republic of the Congo." Moreover, from a genomic point of view, "the diversity of influenza sequences worldwide in any given year appears to be roughly comparable to the diversity of HIV sequences found within a single individual at one time point," noted Korber, colleagues from the Santa Fe Institute, and their collaborators at Technical University of Denmark in a review published several years ago in the British Medical Bulletin.
Hence, instead of basing their vaccine design on antigens from currently circulating strains of HIV, Korber and Bhattacharya take advantage of more than 72,000 HIV-1 genomic sequences stored in a databank that she manages. Referring to the computer as her "lab bench," Korber uses sequence information from samples collected globally as a basis for choosing the most commonly occurring amino acids at key positions in several HIV structural proteins.
Korber says that the process is analogous to determining a "most
DOE Expands Plans for Genomics, Systems Biology
Officials in the Department of Energy (DOE) Office of Biological and Environmental Research and Office of Advanced Scientific Computing Research last year issued an expanded and updated version of DOE Genomics: GTL Roadmap (http://doegenomestolife.org/). The 2005 report outlines a three-phase program extending beyond 16 years, with the initial 8-year phase to emphasize microbial genomics and, later, systems biology as a new "community of scientists" develops. The report defines the "ultimate GTL scientific goal" as being a "predictive system-level understanding of microbiology," noting that these scientific programs will help DOE to meet critical needs, including energy production, environmental remediation, and carbon cycling and sequestration. The DOE Genomics GTL is "a pacesetting program for next-era science, in which all the '-omics' are brought together in an integrated manner," says microbiologist James Tiedje of Michigan State University in East Lansing, Mich. The program thus will bring "the power of big-scale, integrated science, performed by many partners, to microbiology, providing a synergy needed for . . . advances in science and its applications."
Volume 1, Number 3, 2006 / Microbe Y 111 common denominator." However, it proves a far more computationally complex endeavor to identify biochemical features that remain constant within the HIV virus, whose genomics are intensely mercurial, and thus requires the use of LANL supercomputers to calculate values through a specialized code that Bhattacharya developed. "We use data rather than the environment for optimizing genetic fitness," he says.
Based on those computed values, Korber, Bhattacharya, and their collaborators from Duke University Medical Center in Raleigh, N.C., the University of Alabama (UA) in Birmingham, and the UA Hughes Medical Institute synthesized p24 and gp160 HIV consensus sequences for use as candidate vaccine antigens. When tested in vitro, the synthetic antigens cross-react with sera from patients infected with multiple HIV subtypes. When injected into rodents, the antigens readily stimulate antibodies and cytotoxic T-cell responses. "We are already testing the vaccine in macaques and hope the results will be good enough to eventually begin smallscale human trials," Korber says.
"Global consensus sequences and the model of the ancestor are 'central,' and are roughly twice as close to the circulating strains as wild types are to each other," she continues. The group believes computational or rational vaccine design will overcome the challenges of designing effective vaccines to cope with rapidly changing, genetically diverse HIV viruses from geographically dispersed regions. This computational approach, they say, may also help overcome the problems associated with making vaccines against pathogens such as the hepatitis C and Ebola viruses. Coffin and Rainey generated a series of single mutations in the avian retrovirus alpharetrovirus that enable it to infect rodent, cat, dogs, monkey, and human cells in vitro. When these same mutant viruses infect avian cells, the ordinary host for this virus, the cells act dramatically infected and cell death programs are activated.
Janet Yagoda Shagam
Yet, the mutations in the alpharetrovirus were simple, and each one involved a single amino acid change in a surface protein that the virus uses when entering host cells. Presumably, those mutations account for the loss in specificity that ordinarily restricts this virus to avian cells. But, by broadening its host cell range, the mutated virus apparently also sidesteps a critical event in its life cycle. In doing so, it becomes more pathogenic than usual.
"When normal viruses infect a cell, they block the [cell surface] receptor, so that no other virus of their type can get in," Coffin says. But these mutant viruses with altered surface proteins enter cells even if the usual receptor is blocked. Consequently, the mutant viruses flood the cell, making unusually large quantities of viral genomes that trigger cell death programs. Conversely, retroviruses with normal surface proteins remain sensitive to receptor blockade, and thus cannot gain access to the cellular apparatus for reproducing their genomes.
"We hypothesize that although the broad host range allows infection of new hosts, it is advantageous for the virus then to evolve to use a specific receptor found in the new host, so that its pathogenic effect will be less," Coffin says. Such broad-host-range viruses have not been found in nature, perhaps because their surface proteins quickly gain specificity for receptors on the new host cells, reducing associated toxicities. However, he adds, "We've never seen this jump occur in a direct way." "The current work, which evaluates highly pathogenic variants, sheds mechanistic insight into how natural isolates may have arisen," Rainey says. "Existing isolates probably arose from more highly pathogenic predecessors and have attenuated their harmful effects to allow transmission to a large enough number of new hosts to ensure their continued existence."
There is no evidence that HIV mutated to expand its host range into humans, Coffin says, alluding to the virus that is responsible for AIDS in humans. However, like the mutants of avian alpharetrovirus, "HIV-1 can evolve to use different cellular coreceptors once an infection is established, and the use of the alternate coreceptor is associated with cell killing and AIDS disease progression," Rainey points out.
Although these studies focused on a retrovirus, some of the same mechanisms may be in play for very different kinds of viral pathogens, according to Mark J. Federspiel of the Mayo Clinic in Rochester, Minn. "This information on retroviruses may also lead to insights on how other viruses expand their host range-for example, the influenza virus," he says.
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